Compare Illumina, Inc. (ILMN) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs MakeMyTrip Ltd — how do they compare? Illumina, Inc. trades at $190.63 (market cap $27.94B), while MakeMyTrip Ltd trades at $55.14 (market cap $5.05B). The key difference: Illumina, Inc. is far larger — about 5.5× MakeMyTrip Ltd's market cap, and Illumina, Inc. is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| ILMN | MMYT | |
|---|---|---|
Market Cap | $27.94B | $5.05B |
Sector | Health | Technology |
52-Week High | $194.33 | $103.21 |
52-Week Low | $91.00 | $36.30 |
Enterprise Value | $29.33B | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
MakeMyTrip (MMYT) trades at $53.22, down 2.56% on the day, with a bullish technical signal and strong analyst support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.25 exceeding expectations. Revenue for 2025 reached $978.34 million, though 2026 projections show a potential decline in net profit margin to 4.96%. Cash flow from operations remains healthy at $185.29 million, but a significant increase in liabilities is forecasted for 2026.
The outlook for MMYT is positive based on consistent earnings outperformance and a dominant market position in Indian online travel. Key risks include rising debt levels and travel demand volatility. With 72.73% of analysts rating it a Buy, the stock presents a growth opportunity, but investors must monitor execution against heightened financial leverage in the coming year.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
